Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01108679 · ClinicalTrials.gov registry record
Neurocognitive Effects of Buprenorphine Among HIV+ and HIV-Opioid Users
A clinical trial of HIV Infections and HIV, sponsored by Albert Einstein College of Medicine.
- Completed
- Registry status
- 40
- Enrollment target
- 2
- Study locations
NCT01108679 is a study of HIV Infections and HIV that has completed, run by Albert Einstein College of Medicine. The registered enrollment target is 40 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (91% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT01108679, a study of HIV Infections and HIV, has completed, sponsored by Albert Einstein College of Medicine.
- COMPLETED
- Registry status
- 40 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to examine how Buprenorphine, a form of opioid addiction treatment, changes the ability to think and reason among people addicted to opiates, who are either HIV negative or HIV positive. In addition, blood samples will be stored for HIV+ and HIV- individuals who take buprenorphine to study its effect. This study hypothesizes that the HIV positive participants will demonstrate significant improvement in thinking and reasoning ability at 3 and 6 months compared to baseline, but that their thinking and reasoning ability will still be lower than HIV negative participants. This study also hypothesizes the biomarkers in participants' blood samples will be associated with measures of change in thinking and reasoning ability.
Conditions Studied
Study Locations (2)
New York
- Fordham University - The Bronx
- Albert Einstein College of Medicine - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2009-12-01 |
| Est. Completion | 2012-02-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01108679
The ClinicalTrials.gov registry entry for NCT01108679 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (91% lower). The listed sponsor is Albert Einstein College of Medicine, which has 175 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with HIV Infections appearing as the primary indexed condition, and to 0 interventions.
NCT01108679 reports 2 study locations spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT01108679 about?
NCT01108679 is a clinical study titled "Neurocognitive Effects of Buprenorphine Among HIV+ and HIV-Opioid Users". The purpose of this study is to examine how Buprenorphine, a form of opioid addiction treatment, changes the ability to think and reason among people addicted to opiates, who are either HIV negative or HIV positive. In addition, blood samples will be stored for HIV+ and HIV- individuals who take bup...
What is the current status of trial NCT01108679?
This trial is currently completed. The enrollment target is 40 participants. The study started on 2009-12-01. Estimated completion is 2012-02-01.
What conditions does trial NCT01108679 study?
This clinical trial studies the following conditions: HIV Infections, HIV, Opioid-Related Disorders, Cognition, Buprenorphine.
Who is sponsoring clinical trial NCT01108679?
This trial is sponsored by Albert Einstein College of Medicine, which has 175 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01108679 being conducted?
This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk
RECRUITING · NA
-
Community-based Education, Navigation, and Support Intervention for Military Veterans
RECRUITING · NA
-
CAR-T Cells for HIV Infection
RECRUITING · Phase 1
-
A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV
RECRUITING · Phase 1
-
WiseApp for Spanish Speakers Living With HIV
RECRUITING · NA
-
Comprehensive HIV and Harm Prevention Via Telehealth
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.